NeuroSense Therapeutics Ltd. is a clinical-stage biopharmaceutical company focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy показать больше
for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd. is a clinical-stage biopharmaceutical company focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
– моментальные уведомления о рынке акций
